AcelRx Pharmaceuticals, Inc. — FY2017 Form 10-K
Entity and period note: The filing identifies the registrant as AcelRx Pharmaceuticals, Inc., not Talphera, Inc. It covers the fiscal year ended December 31, 2017; quarterly figures below are unaudited.
Business context and reporting period
AcelRx was a development-stage specialty pharmaceutical company focused on sublingual sufentanil products for acute pain in medically supervised settings. Its lead candidate, DSUVIA (DZUVEO outside the U.S.), was not FDA-approved; ZALVISO was approved in Europe and marketed by partner Grünenthal, but AcelRx reported minimal related royalty revenue. The company planned to pursue U.S. approvals and build commercial capabilities, subject to regulatory and funding constraints.
Financial performance and liquidity
Amounts are U.S. dollars in millions unless otherwise stated.
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $8.0 | $17.4 |
| Cost of goods sold | $10.7 | $12.3 |
| Research and development | $19.4 | $21.4 |
| General and administrative | $16.6 | $15.6 |
| Operating loss | $(38.7) | $(32.0) |
| Net loss | $(51.5) | $(43.2) |
| Net loss per share | $(1.10) | $(0.95) |
| Operating cash used | $(29.8) | $(29.4) |
- Revenue fell about 54%, largely reflecting DoD contract revenue declining to $0.9 million from $10.9 million. Grünenthal-related collaboration revenue was $7.1 million, compared with $6.4 million.
- Cost of goods sold exceeded total revenue by about $2.7 million; AcelRx anticipated negative gross margins on ZALVISO supplied to Grünenthal. A $0.4 million inventory impairment was recorded.
- Cash, cash equivalents and short-term investments were $60.5 million at year-end, down from $80.3 million. Working capital was $49.8 million; total assets were $75.6 million and stockholders’ deficit was $36.5 million.
- Long-term debt was approximately $19.1 million, with scheduled maturity in March 2020. The royalty monetization liability was $83.6 million. It is accounted for as a liability and carries estimated non-cash interest at an effective rate of about 14%.
- Financing cash flow included $15.7 million net proceeds from selling 5.4 million shares through the Cantor equity sales agreement. Operating cash use was nearly unchanged year over year.
- FY2017 included $10.7 million of non-cash interest expense on the royalty monetization liability, contributing to the larger net loss. The filing reports no positive operating margin.
Fourth quarter 2017: Unaudited revenue was $0.7 million, operating costs and expenses were $8.5 million, net loss was $9.9 million, and basic and diluted loss per share were each $0.20. Fourth-quarter 2016 revenue was $6.4 million and net loss was $9.7 million.
Material changes versus the prior comparable period
- Annual revenue decreased $9.4 million, mainly because DoD-funded work was substantially completed; the DoD contract was later amended in February 2018 for an additional $0.5 million of services and a one-year extension.
- Net loss increased $8.4 million. Operating loss widened $6.7 million, while non-cash royalty interest expense rose to $10.7 million from $9.4 million.
- R&D expense decreased $2.0 million, as lower DSUVIA spending more than offset increased ZALVISO spending, including the IAP312 study. G&A expense increased $1.0 million, primarily due to DSUVIA pre-commercialization activities.
- Cash and investments declined $19.8 million. Debt was refinanced in March 2017, with a new scheduled maturity of March 2020.
Outlook, risks and unusual items
- After receiving an FDA Complete Response Letter for DSUVIA in October 2017, AcelRx planned to resubmit the NDA in Q2 2018. FDA recommendations included safety data on at least 50 patients dosed at the proposed maximum and revised instructions validated in a human-factors study. Approval was not assured.
- AcelRx planned to resubmit the ZALVISO NDA in H2 2018 after a further Phase 3 study reported a 2.2% device-error rate, below the study’s 5% threshold; FDA acceptance of the results and treatment of inadvertently misplaced tablets remained uncertain.
- The EU review of the DZUVEO marketing application was underway, with a CHMP opinion anticipated in H1 2018. Additional emergency-department or comparator studies could be required.
- Management expected existing capital to fund planned operations through at least the end of Q1 2019, but stated that additional capital would be needed for commercialization and that funding might not be available on acceptable terms. The company expected continued losses and negative operating cash flow.
- Key risks include regulatory delays or rejection, opioid-related restrictions and REMS requirements, limited reimbursement or market acceptance, dependence on Grünenthal, reliance on single-source manufacturers and suppliers, and potential equity dilution or debt-default exposure. Sufentanil is a Schedule II opioid.
- Grünenthal-related ZALVISO royalties were expected to remain minimal in 2018. Under the PDL transaction, PDL receives 75% of European royalties and 80% of the first four commercial milestones, up to a $195 million cap; the filing’s contractual-obligations table estimates $194.9 million of future payments related to the royalty liability.
- The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective. No material legal proceedings were reported.
Important facts for investors to verify
- Whether DSUVIA’s resubmission addressed every FDA request and what approval timing, label limitations, or additional studies followed.
- Whether the ZALVISO NDA was resubmitted and how the FDA assessed device errors and inadvertently misplaced tablets.
- Actual cash burn and financing needs versus management’s stated runway through Q1 2019; the filing does not establish that the runway would be achieved.
- Grünenthal’s commercial sales, AcelRx’s resulting net receipts after PDL’s share, and the cash-flow assumptions underlying the royalty liability.
- Progress and costs for commercial manufacturing, including the planned automated DSUVIA packaging line, supplier qualification, and ability to meet contract obligations.
- Potential dilution, debt repayment requirements, and the restrictions and collateral provisions in the Hercules loan agreement.